tldrdaily.news logo
Tag

Weight Loss Market

All articles tagged with #weight loss market

finance1 year ago

"Predicting Eli Lilly's Path to a $1 Trillion Market Cap"

Eli Lilly's recent success is attributed to its work in the weight-loss market, particularly with the approval of tirzepatide for treating type 2 diabetes and obesity. Analysts predict rapid growth in this market, with estimates of tirzepatide becoming one of the best-selling medicines in the industry. Additionally, the company has made progress in other areas, such as potential Alzheimer's disease therapy and other regulatory nods. With a strong pipeline and underlying business, Eli Lilly is expected to reach a trillion-dollar market capitalization in the next five years, making it a worthwhile investment for the future.

via Yahoo Finance|
#biotech-industry#eli-lilly#finance
businessfinance1 year ago

"Assessing Eli Lilly's Potential to Reach $1 Trillion Market Cap in 5 Years"

Eli Lilly's recent success is attributed to its work in the weight-loss market, particularly with the approval of tirzepatide for treating type 2 diabetes and obesity. Analysts predict rapid sales growth for tirzepatide, potentially reaching $15 billion in the next five years. Additionally, the company has made progress in other areas, such as potential Alzheimer's disease therapy and other regulatory nods for cancer and ulcerative colitis treatments. With a strong pipeline and underlying business, Eli Lilly is expected to reach a trillion-dollar market capitalization in the next five years, making it a promising investment for the future.

via The Motley Fool|
#biotech-industry#businessfinance#eli-lilly
business2 years ago

Eli Lilly's Future Outlook: A Comprehensive Analysis

Eli Lilly, the top healthcare stock with a valuation of $550 billion, is expected to focus on the weight-loss market, which is projected to be worth nearly $300 billion by 2030. With its approved weight-loss treatment Zepbound and ongoing development of a once-daily weight-loss pill, Eli Lilly aims to capture a significant share of this market. The company's annual sales could potentially exceed $50 billion in five years, driven by the success of Zepbound and other growth catalysts in its portfolio. There is a possibility that Eli Lilly could become the first healthcare company to reach a $1 trillion market cap, making it an attractive investment opportunity.

via Yahoo Finance|
#business#eli-lilly#healthcare-stock
pharmaceuticals2 years ago

Roche's $3.1 Billion Acquisition of Carmot Positions It in the Obesity Drug Market

Swiss drugmaker Roche has agreed to acquire obesity drug developer Carmot Therapeutics for $2.7 billion upfront, joining the race to challenge weight-loss drug leaders Novo Nordisk and Eli Lilly. Carmot's lead drug candidate, a once-a-week injection called CT-388, is a dual GLP-1/GIP receptor agonist. Roche aims to develop CT-388 as the best obesity drug in the GLP-1 class, either alone or in combination with other compounds. The weight-loss market is estimated to reach $100 billion, and Roche's move signals its ambition to become a major player in this field.

via Reuters|
#carmot-therapeutics#glp-1-receptor-agonist#obesity-drugs